GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory ...
Four and a half years after the start of the COVID-19 pandemic, people are once again enjoying time with friends and family and doing their favorite things. However, the virus that causes COVID-19 ...